- Home
- SNGX vs RDHL Comparison
SNGX vs RDHL Comparison
Compare SNGX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- RDHL
- Stock Information
- Founded
- SNGX 1987
- RDHL 2009
- Country
- SNGX United States
- RDHL Israel
- Employees
- SNGX N/A
- RDHL N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- RDHL Health Care
- Exchange
- SNGX Nasdaq
- RDHL Nasdaq
- Market Cap
- SNGX 9.6M
- RDHL 8.6M
- IPO Year
- SNGX 1987
- RDHL N/A
- Fundamental
- Price
- SNGX $3.16
- RDHL $6.99
- Analyst Decision
- SNGX
- RDHL
- Analyst Count
- SNGX 0
- RDHL 0
- Target Price
- SNGX N/A
- RDHL N/A
- AVG Volume (30 Days)
- SNGX 46.1K
- RDHL 21.2K
- Earning Date
- SNGX 11-08-2024
- RDHL 12-27-2024
- Dividend Yield
- SNGX N/A
- RDHL N/A
- EPS Growth
- SNGX N/A
- RDHL N/A
- EPS
- SNGX N/A
- RDHL N/A
- Revenue
- SNGX $364,183.00
- RDHL $3,707,000.00
- Revenue This Year
- SNGX N/A
- RDHL $224.90
- Revenue Next Year
- SNGX $76.64
- RDHL $82.69
- P/E Ratio
- SNGX N/A
- RDHL N/A
- Revenue Growth
- SNGX N/A
- RDHL N/A
- 52 Week Low
- SNGX $1.83
- RDHL $6.35
- 52 Week High
- SNGX $19.20
- RDHL $43.50
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- RDHL 42.91
- Support Level
- SNGX $2.93
- RDHL $7.09
- Resistance Level
- SNGX $3.35
- RDHL $7.44
- Average True Range (ATR)
- SNGX 0.19
- RDHL 0.53
- MACD
- SNGX -0.01
- RDHL -0.03
- Stochastic Oscillator
- SNGX 37.10
- RDHL 12.36
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.